Thiostrepton is under clinical development by RS Oncology and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Thiostrepton’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Thiostrepton overview

RSO-021 is under development for the treatment of breast cancer, malignant mesothelioma, malignant pleural effusion (MPE), Malignant Pleural Mesothelioma, non-small cell lung cancer and ovarian cancer. It is administered through intrapleural route. The drug candidate acts by targeting peroxiredoxin 3 (PRX3).

RS Oncology overview

RS Oncology is developing novel therapeutics which modulate mitochondrial pathways that drive diseases of oxidative stress. RS Oncology is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Thiostrepton’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.